-
KemPharm's ADHD Candidate Meets Efficacy, Safety Trial Endpoints
Monday, July 9, 2018 - 11:42am | 303Read More...KemPharm Inc (NASDAQ: KMPH) shares plunged nearly 7 percent off Monday’s open despite news that its KP415 candidate for ADHD met primary and secondary endpoints in a pivotal efficacy and safety trial. What Happened The drug demonstrated statistically significant improvement on the SKAMP scale...
-
What Kids Don't Want Their Parents To Know About Fidget Spinners
Friday, May 5, 2017 - 9:51am | 680Read More...It’s every parent’s dream for their child to beg for a toy that costs as little as $5 and improves their focus, lowers their anxiety and relieves their stress. Anyone who has browsed Amazon.com, Inc. (NASDAQ: AMZN), eBay Inc (NASDAQ: EBAY) or Etsy Inc (NASDAQ: ETSY) looking for a fidget...
-
KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
Thursday, January 12, 2017 - 3:34pm | 855Read More...On Monday, KemPharm Inc (NASDAQ: KMPH) reported encouraging results from its exploratory Phase 1 study assessing the pharmacokinetics, safety and intranasal abuse potential of KP511 Active Pharmaceutical Ingredient, an investigational pain treatment prodrug. As per the analysis, KP511 demonstrated...
-
Alcobra Shares Initiated At Buy; Cantor Sees 'Greater Opportunity For Success'
Tuesday, June 7, 2016 - 9:29am | 195Read More...Cantor Fitzgerald's Maria Goldstein initiated Alcobra Ltd(NASDAQ: ADHD) at Buy with a price target of $16.00. Goldstein believes Alcobra's MDX, a non-stimulant-based drug to treat ADHD, has "an opportunity to achieve a statistically significant result with substantive hanged incorporated in the...
-
Shire Just Took Another Step Forward With Its ADHD Drug
Monday, April 4, 2016 - 5:05pm | 287Read More...BTIG's Timothy Chiang said Shire PLC (ADR) (NASDAQ: SHPG) moved one step closer to satisfying the FDA's request for clinical data with its SHP465 (a three-bead formulation of mixed amphetamine salts) compound for the treatment of ADHD (Attention-Deficit Hyperactivity Disorder). The...
